Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by javaman12on Nov 02, 2024 9:35pm
52 Views
Post# 36294018

RE:I sent this e-mail to James Passin Today!

RE:I sent this e-mail to James Passin Today!I also sent a copy of my last e-mail (my e-mail to James Passin) to Ursula Bechert, DVM, PhD at SprayVac.

[url=ursula@spayvac.com][/url]

I know that I am doing a lot of speculating but how are we to supposed to know what may be going on behind the scenes if we don't ask the right kind of question? Investors want to know!

Here is the main impart of my message to Ursula [ I could have composed it better ]
:


"...I sent this e-mail [the contents of my previous post by Java] to James Passin today and posted it on Stockhouse, an investment forum. You might be interested in my commentary, especially about the research that Toralgen, a potential company start-up has been doing with its novel approach to oral medications. I am writing this article from an investors point of view in BioVaxys.

Maybe fish could still actually consume food with nano sized drugs [while effectively medicating them] encapsulated inside [the feed]? I would really like your perspective on this matter and I am certain that all potential BioVaxys shareholders would also like to be better informed! [Ursula had previously told me that encapsulated fertility drugs would not work because they could not effectively pass through the gut and enter the blood stream intact]

If I had found about the work that Toralgen has been doing, I am most certain that you and James Passin [have also heard this news]! There are no secrets on the internet! [Toralgen claims that their pill formulations could work afterall!]

Is Toralgen's work a part of the reason that SpayVac has been delaying its decision with respect to controlling the fertility of fish populations? Or are you still working on the injection vaccination technique [with respect to farmed fish]? The tardiness of your decision is holding back our share price! Sad to say! We [seem to have] no other [near term] revenue stream, except for this license!

With respect to the fish farm market, are you also waiting for the final results from Toralgen? That could still take [some] months or years, could it not? Are you providing them with some of the seed money that they are presently spending in return for future shares [that you might receive] after some IPO [by Toralgen]?

Perhaps James Passin is also interested in doing something similar.

Why don't you [managers] af SpayVac, Toralgen, and BioVaxys combine forces as a single corporate entity to more easily fund your work and reward any potential new investors?

Does your company always intend to remain private or could you also be planning to do a corporate IPO at some near term date? There are many good options available to achieve a better success to maximize growth! But for a small company like SpayVac, what do you think that your best solution may happen to be? Is it [better to grow] by continuing on as a private entity or as a larger part of a rapidly growing public company? Certainly as a smaller private entity, it will eventually grow larger. But how long will it take?


Ursula, this is how investors think! We soak up valuable information like a sponge! I understand from a few minutes of research that you love wild horses wherever they roam, wildly and free. For many, this may come across as an old school, romantic notion. But for many outdoors lovers, it is not!

When it comes to wild animals in the prairie or the bush, they may come in conflict with the needs of farmers and ranchers. But like all free spirited, wild running creatures, their numbers do need to be kept under control or the demand for their extermination in the future could drive many of them, completely out of existence!

What would be the best way to accomplish this kind of noble goal and gain acceptance from a skeptical public?

Clearly their population control is the answer and this noble idea needs to be properly promoted, everywhere in the world!

What is the best manner for their population control if the drug to effect this need is already available?

Should these wild creatures be given a single injection [the BioVaxys product} or should [they be offered a potential Toralgen product] some feed infused with medication that could be [simply] tossed in their direction..."

What choice is best?

Only SpayVac will determine what will be their best course of action in the future!

Maybe a better approach to teamwork could be the better choice to make!

Small corporate entities, when combined together, could grow faster!

                                       All the best, Java



 


 

 

 

 

<< Previous
Bullboard Posts
Next >>